Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 11/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014022 | 1.00 | TSHR (0.42) | TSHRCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL27349177 | 1.00 | TSHR (0.42) | TSHRCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL29946019 | 1.00 | TSHR (0.42) | TSHRCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL23526260 | 1.00 | TSHR (0.42) | TSHRCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL27224396 | 0.98 | ALDH1A1 (0.43) | TSHRCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL29755437 | 0.98 | ALDH1A1 (0.43) | TSHRCYP1A2CYP3A4CYP2D6NFKB1 | |
| Hydrochloric Acid SCHEMBL27224651 | 0.98 | ALDH1A1 (0.43) | TSHRCYP1A2CYP3A4CYP2D6NFKB1 | |
| SCHEMBL23563886 | 0.86 | TSHR (0.43) | TSHRALDH1A1SOS1NISCHAR | |
| Trifluoroacetic Acid SCHEMBL31463924 | 0.85 | AR (0.39) | SOS1ARL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL31463954 | 0.85 | AR (0.39) | SOS1ARL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250270220-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4600243-A2 | NOVEL BICYCLIC HETEROCYCLYL COMPOUNDS AND USE THEREOF | Jeil Pharmaceutical Co., Ltd. (KR) | 2025-08-13 | — | — | EP | disclosed |
| US-12304915-B2 | SOS1 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4543450-A1 | SALTS OF SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250059182-A1 | SOS1 INHIBITORS | MIRATI THERAPEUTICS, INC | 2025-02-20 | — | — | US | disclosed |
| EP-4417607-A1 | HETEROCYCLIC COMPOUND AS SOS1 INHIBITOR AND USES THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-08-21 | — | — | EP | disclosed |
| CN-118126035-A | Cycloalkyl or heterocycle substituted benzo or pyridopyridazine, and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117957226-A | Heterocyclic compounds as SOS1 inhibitors and uses thereof | 南京再明医药有限公司 | 2024-04-30 | — | — | CN | disclosed |
| WO-2024083257-A1 | SOS1 PROTEIN DEGRADATION AGENT AND USE THEREOF | 上海领泰生物医药科技有限公司 | 2024-04-25 | — | — | WO | disclosed |
| WO-2023109929-A1 | HETEROCYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137886-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023041049-A1 | HETEROCYCLIC COMPOUND AS SOS1 INHIBITOR AND USES THEREOF | 江苏先声药业有限公司 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023280317-A1 | BENZYLAMINO TRICYCLIC COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022271679-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115135315-A | SOS1 inhibitors | 米拉蒂治疗股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
| US-20210188857-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382290-A1 | SALTS OF SOS1 INHIBITORS | SOS1, SOS2, SOST | TSHR 3559/4885CYP1A2 4661/4885CYP3A4 4750/4885 |
| US-12304915-B2 | SOS1 inhibitors | SOS1, SOS2, SAV1 | TSHR 3357/4885CYP1A2 4781/4885CYP3A4 4860/4885 |
| US-20250059182-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | TSHR 3618/4885CYP1A2 4753/4885CYP3A4 4856/4885 |
| US-20230137886-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | TSHR 3357/4885CYP1A2 4781/4885CYP3A4 4860/4885 |
| US-20250270220-A1 | SOS1 INHIBITORS | SOS1, SOS2, SAV1 | TSHR 3357/4885CYP1A2 4781/4885CYP3A4 4860/4885 |
| US-20210188857-A1 | SOS1 INHIBITORS | SOS1, SOS2, SOST | TSHR 3618/4885CYP1A2 4753/4885CYP3A4 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.